NEW YORK (GenomeWeb) – Biotech has been an attractive sector for investors over the past few years, but omics and molecular diagnostics companies have encountered regulatory uncertainty and reimbursement headwinds that have led some investors to divert capital to more certain sources of return.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.